We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

193 hedge funds and large institutions have $644M invested in Revance Therapeutics, Inc. in 2023 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 74 increasing their positions, 49 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

242% more call options, than puts

Call options by funds: $18M | Put options by funds: $5.27M

51% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 49

34% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 32

4% more funds holding

Funds holding: 186 → 193 (+7)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

28% less capital invested

Capital invested by funds: $893M → $644M (-$249M)

Holders
193
Holders Change
+7
Holders Change %
+3.76%
% of All Funds
2.81%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
43
Increased
74
Reduced
49
Closed
32
Calls
$18M
Puts
$5.27M
Net Calls
+$12.7M
Net Calls Change
+$9.27M

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$9.47M
2
CIBC Asset Management
CIBC Asset Management
Ontario, Canada
+$6.72M
3
Franklin Resources
Franklin Resources
California
+$5.83M
4
BlackRock
BlackRock
New York
+$5.71M
5
Walleye Capital
Walleye Capital
New York
+$5.1M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$15.5M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$11.2M
3
Invesco
Invesco
Georgia
-$10.6M
4
DM
Deerfield Management
New York
-$9.98M
5
Marshall Wace
Marshall Wace
United Kingdom
-$8.19M
Name Holding Trade Value Shares
Change 		Change in
Stake
Zurich Cantonal Bank
126
Zurich Cantonal Bank
Switzerland
$159K – – –
FCH
127
Freestone Capital Holdings
Washington
$158K – – –
NSEDCP
128
NJ State Employees Deferred Compensation Plan
New Jersey
$157K – – –
CF
129
Centaurus Financial
California
$155K -$56.7K -6,915 -28%
SXL
130
Summit X LLC
Missouri
$153K -$2.11K -257 -1%
Public Employees Retirement Association of Colorado
131
Public Employees Retirement Association of Colorado
Colorado
$134K – – –
FWM
132
Fairhaven Wealth Management
Illinois
$131K +$122K +14,859 New
SIG
133
Sargent Investment Group
Maryland
$121K +$113K +13,822 New
VI
134
Versor Investments
New York
$119K +$111K +13,500 New
SRL
135
Scientech Research LLC
New Jersey
$116K +$108K +13,225 New
Millennium Management
136
Millennium Management
New York
$116K -$1.32M -161,120 -92%
AI
137
Accredited Investors
Minnesota
$113K – – –
YC
138
Yarbrough Capital
Tennessee
$107K – – –
MM
139
MQS Management
New York
$106K +$99.1K +12,094 New
NA
140
Nottingham Advisors
New York
$105K – – –
AB
141
Amalgamated Bank
New York
$103K -$6.74K -822 -7%
Victory Capital Management
142
Victory Capital Management
Texas
$92.8K +$86.5K +10,554 New
CUAMC
143
China Universal Asset Management Company
China
$89.3K +$64.8K +7,905 +351%
QOP
144
Quinn Opportunity Partners
Virginia
$87.9K +$81.9K +10,000 New
A
145
AlphaQuest
New York
$83.8K +$78.1K +9,532 New
EC
146
EntryPoint Capital
New York
$83.6K +$77.9K +9,506 New
AIP
147
Ameritas Investment Partners
Nebraska
$72.9K – – –
Canada Pension Plan Investment Board
148
Canada Pension Plan Investment Board
Ontario, Canada
$67.7K – – –
Canada Life
149
Canada Life
Manitoba, Canada
$66K – – –
TRCT
150
Tower Research Capital (TRC)
New York
$60K +$48.2K +5,884 +627%
4 5
6
7 8

RVNC Hedge Fund Activity: Q4 2023 in Review

193 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q4 2023, worth a combined $644M — down 28% from $893M a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new RVNC positions and 32 closed out — a net gain of 11 holders — while 74 added to existing stakes and 49 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $9.47M. The largest seller was Fidelity Investments, cutting an estimated $15.5M.

  • 193 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q4 2023, up from 186 in Q3 2023.
  • Funds reported $644M of Revance Therapeutics, Inc. stock for Q4 2023, down 28% quarter-over-quarter.
  • 43 funds opened new Revance Therapeutics, Inc. positions in Q4 2023 and 32 closed out, a net change of +11 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q4 2023 was Morgan Stanley, an estimated $9.47M added.
  • The largest Revance Therapeutics, Inc. seller in Q4 2023 was Fidelity Investments, an estimated $15.5M sold.

Based on aggregated 13F filings for Q4 2023.